Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target

Boyle, J.G., Salt, I.P. and McKay, G.A. (2010) Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target. Diabetic Medicine, 27(10), pp. 1097-1106. (doi:10.1111/j.1464-5491.2010.03098.x) (PMID:20854376)

Full text not currently available from Enlighten.

Abstract

Clinical studies in Type 2 diabetes mellitus have shown that the effects of metformin go beyond improving HbA1c and include reductions in cardiovascular endpoints. Metformin therapy has been widely used in the treatment of Type 2 diabetes for many years, yet the precise mode of action remains uncertain. It has recently been proposed that metformin-mediated stimulation of hepatic AMP-activated protein kinase (AMPK) underlies the hypoglycaemic effects of metformin. AMPK is a heterotrimeric enzyme that is expressed in many tissues and plays a central role in the regulation of energy homoeostasis. Furthermore, there is increasing evidence that AMPK is implicated in the pathophysiology of cardiovascular and metabolic diseases. The generation of more specific and potent activators of AMPK, however, could have additional metabolic and vascular benefits for patients with Type 2 diabetes.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Boyle, Dr James and McKay, Dr Gerard and Salt, Dr Ian
Authors: Boyle, J.G., Salt, I.P., and McKay, G.A.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Diabetic Medicine
ISSN:0742-3071
Published Online:21 July 2010

University Staff: Request a correction | Enlighten Editors: Update this record